Sarepta Therapeutics Inc (NASDAQ:SRPT) closed Wednesday’s trading session at $132.25, just days after it announced that it is opening the Route 79, The Duchenne Scholarship Program, for the second year.

The company revealed that Route 79, The Duchenne Scholarship Program was scheduled to run for the second year and that aspiring applicant can start applying to join the program. An independent committee that is part of the Duchenne community members will narrow down the applicants to 20 lucky contestants who will then be awarded up to $5,000 in academic scholarships. The committee will select the 20 winners based on a personal essay and community involvement.

“In 2018, we launched Route 79, The Duchenne Scholarship Program, supporting the educational goals of students living with Duchenne,” stated Sarepta CEO, Douglas Ingram.

The CEO also noted that the company received an overwhelming response about Route 79 in the first year and the quality of applications was quite remarkable. Sarepta is also excited for this year’s Duchenne Scholarship Program, and it also looks forward to evaluating applications from students that hope to benefit from the initiative.

The company designed the Route 79 program so that it could provide opportunities for students with Duchenne to pursue further education after high school. Duchenne is caused by a dystrophin gene coding error or mutation. Dystrophin is a vital protein that is one of the major building blocks for muscle structure, preservation, and function. The company derived the name “Route 79” from the 79 exons that are part of the dystrophin gene.

Aspiring applicants will only be eligible for a scholarship application from the Route 79 program if they have been accepted into an accredited university or college. A Duchenne muscular dystrophy diagnosis is also a qualification criterion for the applicants. The company also revealed that winners or applicants that received Route 79 scholarship funds in the 2018-2019 academic year would also be allowed to apply for the 2019-2020 academic year. This means that students stand a chance to win the funding multiple times. Qualified students have until April 30 this year to submit their applications.

Looking for the next Pfizer (PFE) or Johnson&Johnson (JNJ)? Take advantage of Kyle Dennis’ free biotech trader’s handbook and how he made his first $2.9 Million in the market. The smart money is pouring into this sector and you’ll want to grab a piece of this action! Which company is next to explode?